Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in a deal potentially worth more than $1 billion.

Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Suzhou Sinovent and SinoMab Bio in a $561 million deal. Shanghai Everest Medicines announced a $500 million two-part deal with Providence Therapeutics for mRNA products.